A Study on Association Between Homologous Recombination Genes and the Homologous Recombination Deficiency Status in Chinese Population With Epithelial Ovarian Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Epithelial Ovarian Cancer
- Sponsor
- Lei Li
- Enrollment
- 240
- Locations
- 1
- Primary Endpoint
- Homologous recombination deficiency (HRD) score
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients is little known. This study would recruit 400 Chinese EOC patients with known targeted gene mutations via a multi-panel testing of 27 genes, including BRCA1/BRCA2. All patients accept evaluation of HRD model, which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients, and a potential explanation of platinum-resistance in such population.
Investigators
Lei Li
Professor
Peking Union Medical College Hospital
Eligibility Criteria
Inclusion Criteria
- •Aged 18 years or older
- •Pathological confirmation of epithelial ovarian cancer
- •With available tumor tissues
- •Given consents to participate the study
Exclusion Criteria
- •Not meeting all of the inclusion criteria
Outcomes
Primary Outcomes
Homologous recombination deficiency (HRD) score
Time Frame: Two years
The HRD score for individual patient is a scale describing her HRD status. The score model is calculated by the analysis for three types of important molecular mechanism: loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The minimum value is 0, but the maximun value is not available. Higher scores mean more sensitivity to poly-ADP-ribose polymerase inhibitor.
Secondary Outcomes
- Overall survival(Five years)
- Progression-free survival(Five years)